The National Health Surveillance Agency (Anvisa) granted, this Tuesday (23), the definitive registration to the vaccine of Pfizer / BioNTech against Covid-19. The vaccine is the first vaccine to obtain the definitive health record in Brazil, but it is not yet available in the country. (See the full Anvisa note at the end of the report).
THE G1 questioned the Ministry of Health about a forecast of purchasing the vaccine, but, until the last update of this report, had not received a response.
The two vaccines being applied in Brazil are Oxford and CoronaVac, but both have authorization for emergency use, not the definitive registration.
The Pfizer vaccine was one of four tested in Brazil. Earlier this year, the drugmaker said it had offered 70 million doses of the vaccine to the Brazilian government for delivery in December, but the offer was declined. The Ministry of Health said that the doses proposed by Pfizer would cause “frustration” to Brazilians.
What vaccine is this? Pfizer Biontech
What vaccine is this? Pfizer Biontech.
See the full Anvisa note:
“As Chief Executive Officer of the National Health Surveillance Agency, I inform you with great satisfaction that, after a seventeen-day review period, the General Management of Medicines, of the Second Board, granted the first vaccine registration against Covid 19, for use in the Americas.
The immunizer from the Pfizer / Biontech Laboratory had its safety, quality and efficacy, assessed and certified by the technical team of Anvisa servers that continues in its work to protect the health of the Brazilian citizen.
We hope that other vaccines are soon being evaluated and approved.
This is our commitment. “CEO Antonio Barra Torres
Among the reference authorities by the Pan American Health Organization (PAHO), Anvisa is the first to grant the registration of a Covid-19 vaccine, with 7 (seven) certified manufacturing sites, reflecting the Agency’s dedication, planning and commitment combating the pandemic. Registration paves the way for the introduction of a vaccine on the market with all the safeguards, controls and obligations resulting from this concession. Director Meiruze Freitas.